Every 10-Q that Lyell Immunopharma, Inc. (LYEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LYEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LYEL filings page.
Lyell Immunopharma, Inc. reported a development‑stage loss profile for the quarter ended June 30, 2026 while maintaining substantial liquidity. Net loss for the quarter was $44,755 (in thousands) on revenue of $4 (in thousands); for the first six months, net loss was $68,908 (in thousands), down from $94,879 (in thousands) a year earlier.
Cash and cash equivalents were $72,985 (in thousands) and total cash equivalents and fixed income marketable securities were $215,893 (in thousands), supporting total assets of $311,153 (in thousands) and stockholders’ equity of $233,815 (in thousands). Net cash used in operating activities for the six months was $72,432 (in thousands), partially offset by $50,000 (in thousands) of proceeds from a securities purchase agreement equity issuance and $1,696 (in thousands) from at‑the‑market share sales.
The company continues to advance its cell therapy pipeline, including pivotal PiNACLE and PiNACLE‑H2H trials for its dual‑targeting CD19/CD20 CAR T‑cell candidate ronde‑cel in large B‑cell lymphoma, and development of LYL273 for GCC‑expressing solid tumors. Management states existing working capital is sufficient to fund operations for at least 12 months from issuance of these financial statements.
Lyell Immunopharma, Inc. reported a narrower quarterly loss while advancing late‑stage cell therapy programs for lymphoma and colorectal cancer. For the three months ended March 31, 2026, revenue was minimal at $2 thousand, reflecting its development-stage focus.
Research and development expense fell to $36.6 million and general and administrative expense to $9.6 million, contributing to a reduced net loss of $24.2 million versus $52.2 million a year earlier. Results were aided by a $17.6 million gain from settling a securities purchase agreement put/call and higher interest income.
Lyell strengthened its balance sheet with equity financings, including $50.0 million from a milestone securities purchase closing, a $43.9 million PIPE and $1.7 million from at‑the‑market share sales. As of March 31, 2026, it held $90.8 million in cash and cash equivalents and $170.2 million in marketable securities, and management believes existing resources fund operations for at least 12 months.
Lyell Immunopharma (LYEL) reported Q3 2025 results highlighted by continued R&D investment, a narrowed quarterly loss, and a mid‑year capital raise. The company recorded revenue of $15 thousand and a net loss of $38.8 million, improving from a $44.6 million loss a year ago. Operating expenses were $37.3 million, with research and development at $28.2 million and general and administrative at $10.7 million. Interest income contributed $3.3 million. Year‑to‑date, net loss was $133.7 million.
Liquidity remained strong. Cash and cash equivalents were $123.6 million and marketable securities were $196.0 million as of September 30, 2025, for total current liquid investments of $319.6 million. Net cash used in operating activities was $117.8 million for the nine months. In July, the company raised $50.0 million by issuing 3,753,752 shares at $13.32 per share under a Securities Purchase Agreement and recognized a related SPA put/call asset. A 1‑for‑20 reverse stock split was effected on May 30, 2025. Shares outstanding were 19,294, as of quarter‑end, and 21,218,217 as of November 10, 2025.
The company issued 625,000 shares valued at $5.9 million upon achieving an ImmPACT milestone. It also recorded a $1.4 million impairment tied to closing its West Hills facility after transitioning manufacturing to its LyFE center in Bothell, WA.
Lyell Immunopharma reported continued clinical progress on its lead dual-targeting CD19/CD20 CAR T candidate LYL314 and detailed mid-year financials. Total assets were $385.5 million, down from $490.9 million, driven by declines in cash and marketable securities. Cash and cash equivalents stood at $98.8 million with current marketable securities of $178.0 million, and management believes available funds are sufficient to support operations at least 12 months from the issuance of these statements.
Operating results reflect ongoing development spending: six-month R&D expense was $78.3 million and net loss was $94.9 million versus $106.5 million a year earlier, while net cash used in operating activities was $89.2 million. Clinically, Lyell advanced LYL314 into the pivotal PiNACLE trial and presented Phase 1/2 data showing an 88% overall response rate and 72% complete response rate in the 3L+ cohort with median follow-up of nine months. Subsequent events include issuance of 625,000 shares to satisfy a contingent consideration milestone and a July 2025 $50.0 million gross private placement.